Innovative Device-Based Treatments for Hypertension
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpaf235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Min Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical Unive…. Hauptthemen laut MEDLINE: Hypertension, Blood Pressure, Sympathectomy, Electric Stimulation Therapy. Die Arbeit nennt 113 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
The World Health Organization estimates that the number of people living with hypertension [blood pressure (BP) of ≥140 mmHg systolic or ≥90 mmHg diastolic or on medication] doubled between 1990 and 2019, from 650 million to 1.28 billion. Elevated BP is associated with increased risks of stroke, coronary artery disease, heart failure, and chronic kidney disease. Resistant hypertension is defined as office BP ≥140/90 mmHg despite treatment with 3 classes of antihypertensive agents (including a diuretic) at maximally tolerated doses, or the need for 4 or more agents regardless of BP level. Device-based antihypertensive therapies primarily target autonomic nervous system through techniques, such as renal denervation, carotid baroreceptor activation, and carotid body ablation. This review outlines the pathophysiological basis of selected interventions, critically evaluates existing clinical evidence, and highlights future directions for their development and integration into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Cardiology, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
ORCID-Profile: Peng Li
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhang, M., Li, P., & Sheng, Y. (2025). Innovative Device-Based Treatments for Hypertension. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf235
Vancouver
Zhang M, Li P, Sheng Y. Innovative Device-Based Treatments for Hypertension. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf235
BibTeX
@article{Zhang2025,
author = {Zhang, Min and Li, Peng and Sheng, Yanhui},
title = {Innovative Device-Based Treatments for Hypertension},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpaf235}
}
EUVIMED